DBV Technologies S.A. earnings per share and revenue
On Oct 28, 2025, DBVT reported earnings of -0.24 USD per share (EPS) for Q3 25, beating the estimate of -0.25 USD, resulting in a 4.95% surprise. Revenue reached 2.77 million, compared to an expected 661.55 thousand, with a 319.32% difference. The market reacted with a -2.19% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 2 analysts forecast an EPS of -0.11 USD, with revenue projected to reach 618.12 thousand USD, implying an decrease of -54.17% EPS, and decrease of -77.72% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were DBV Technologies S.A.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, DBV Technologies S.A. reported EPS of -$0.24, beating estimates by 4.95%, and revenue of $2.77M, 319.32% above expectations.
How did the market react to DBV Technologies S.A.'s Q3 2025 earnings?
The stock price moved down -2.19%, changed from $15.55 before the earnings release to $15.21 the day after.
When is DBV Technologies S.A. expected to report next?
The next earning report is scheduled for Mar 23, 2026.
What are the forecasts for DBV Technologies S.A.'s next earnings report?
Based on 2
analysts, DBV Technologies S.A. is expected to report EPS of -$0.11 and revenue of $618.12K for Q4 2025.